ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 2...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 2...
Source route
Continue on jnj.com
Leave the platform to read the original full article on the publisher site.
Source: Johnson & Johnson News
Scope: Industry
Related coverage
More related coverage
News and Events
Stay informed with the latest Sanofi investor news, financial results, earnings calls, and key event...
Philips wins FDA clearance for imaging device developed with Edwards
AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
Data highlights efficacy and safety of risankizumab in psoriatic disease, including high impact area...
Press releaseMar 27, 2026Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated…
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven...